Skip to main content

Day: March 7, 2022

NCS Multistage Holdings, Inc. Announces Fourth Quarter and Full Year 2021 Results

Fourth Quarter ResultsTotal revenues of $36.1 million, a 32% year-over-year increase and an 11% increase compared to the third quarter of 2021 Net income of $1.7 million as compared to $8.6 million and $2.8 million in the fourth quarter of 2020 and the third quarter of 2021, respectively, and earnings per diluted share of $0.68; adjusted net income of $1.2 million and adjusted earnings per diluted share of $0.48 Adjusted EBITDA of $6.5 million, a $3.5 million improvement compared to the fourth quarter of 2020 and a $2.3 million improvement compared to the third quarter of 2021 Net cash provided by operating activities, free cash flow and free cash flow after distributions to non-controlling interest of $11.6 million, $11.1 million and $8.4 million, respectively, for the year ended December 31, 2021 $22.2 million in cash and $7.8 million...

Continue reading

Valley National Bancorp Receives Final Regulatory Approvals and Announces the Anticipated Closing Date of the Acquisition of Bank Leumi USA

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) — Valley National Bancorp (NASDAQ:VLY) (“Valley”) announced today that is it has received all regulatory approvals in connection with the previously announced acquisition of Bank Leumi Le-Israel Corporation, the US subsidiary of Bank Leumi Le-Israel B.M., and parent company of Bank Leumi USA.    Valley had previously announced receipt of regulatory approval from the Federal Reserve Bank of New York and the Office of the Comptroller of the Currency. Additional regulatory approvals, including by the New York State Department of Financial Services and the Bank of Israel, were recently received. Valley’s shareholders approved the issuance of Valley stock in connection with the merger on January 13, 2022. Valley anticipates that the closing of the merger will occur on April 1, 2022, subject...

Continue reading

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlights

 Completed dosing in Phase 2a clinical trial of ETX-810 in subjects with diabetic peripheral neuropathic pain; topline data to be presented in 1H 2022 Interim data from Phase 1b clinical trial of ETX-155 in subjects with photosensitive epilepsy to be presented in 1H 2022 Submitted Investigational New Drug (IND) application for ETX-155 to the U.S. Food and Drug Administration (FDA)’s psychiatry division SEATTLE and CAMBRIDGE, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today reported financial results and business highlights for the quarter...

Continue reading

HighPeak Energy, Inc. Announces Fourth Quarter 2021 Results and 2022 Outlook

FORT WORTH, Texas, March 07, 2022 (GLOBE NEWSWIRE) — HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the fourth quarter 2021 and reaffirmed its 2022 outlook. The Company completed its business combination on August 21, 2020 and consequently, the following operational and financial data refer to the three months and year ended December 31, 2021 and the three months ended December 31, 2020 and the period from August 22, 2020 through December 31, 2020 (the “Successor periods”) and the period from January 1, 2020 through August 21, 2020 (the “Predecessor period”). Fourth Quarter 2021 and Early 2022 HighlightsFourth quarter 2021 sales volumes of 14,881 barrels of crude oil equivalent per day (“Boe/d”), an increase of approximately 81% compared with third quarter...

Continue reading

Clarus Reports Record Fourth Quarter and Full Year 2021 Results

– Sales in the Fourth Quarter of 2021 Increased 56% Year-Over-Year to a Record $118.2 Million; Sales for the Full Year 2021 Increased 68% to a Record $375.8 Million – – Expects Full Year 2022 Sales of $470.0 Million and Adjusted EBITDA of $78.0 Million – – Expects Full Year 2022 Free Cash Flow of $50.0 to $60.0 Million – SALT LAKE CITY, Utah, March 07, 2022 (GLOBE NEWSWIRE) — Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor and consumer enthusiast markets, reported financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Financial Summary vs. Same Year‐Ago QuarterRecord sales of $118.2 million increased 56%. Gross margin improved 60 basis points to 36.1%; adjusted gross margin increased by 120 basis points to 37.2%. Net income...

Continue reading

AvidXchange Announces Fourth Quarter & Full Year 2021 Financial Results

–Fourth quarter 2021 revenue and Adjusted EBITDA above previous guidance –2022 financial outlook highlights solid operating momentum and financial position CHARLOTTE, N.C., March 07, 2022 (GLOBE NEWSWIRE) — AvidXchange Holdings, Inc. (Nasdaq: AVDX), a leading provider of accounts payable (AP) automation software and payment solutions for middle market businesses and their suppliers, today announced financial results for the fourth quarter and full year ended December 31, 2021. “2021 was an extraordinary year for AvidXchange. We completed our transition to a public company and raised a significant amount of strategic capital while ending the year with solid operating results that outperformed expectations. We believe our across-the-board strong fourth quarter and full year 2021 results and outperformance relative to...

Continue reading

Rover Reports Fourth Quarter and Full Year 2021 Financial Results

Rover – Bookings + GBV Rover – Bookings + GBVFourth quarter revenue increases to $38 million, up 41% from fourth quarter 2019 Record fourth quarter GBV of $166 million, up 44% from fourth quarter 2019 Fourth quarter new bookings of 215,000, up 30% from fourth quarter 2019SEATTLE, March 07, 2022 (GLOBE NEWSWIRE) — Rover Group, Inc. (“Rover”) (NASDAQ: ROVR), the world’s largest online marketplace for pet care, today announced financial results for the fourth quarter and full year ended December 31, 2021. “I am thrilled with the results our team delivered in a challenging and unpredictable year. We ended 2021 performing better than expected across key metrics such as revenue, unit economics, and Adjusted EBITDA,” said Rover co-founder and CEO, Aaron Easterly. “While we now believe pandemic dynamics will persist well...

Continue reading

thredUP Announces Fourth Quarter and Full Year 2021 Results

All-time quarterly revenue high of $72.9 million, representing 68% growth year-over-year. Fourth quarter gross margin of 66% and gross profit growth of 62% year-over-year. Annual revenue of $251.8 million, representing 35% growth year-over-year. Annual gross margin of 70.7% and gross profit growth of 39% year-over-year. Record number of Active Buyers of 1.7 million and Orders of 1.7 million in Q4 2021, representing growth of 36% and 69% year-over-year, respectively. Record annual orders of 5.3 million, representing growth of 34% year-over-year. Remix acquisition closed in Q4 2021, kickstarting our international expansion. Established new Resale-as-a-Service (RaaS) programs with adidas, Crocs, and Michael Stars.OAKLAND, Calif., March 07, 2022 (GLOBE NEWSWIRE) — ThredUp Inc. (Nasdaq: TDUP), one of the largest online resale platforms...

Continue reading

Infrastructure and Energy Alternatives Announces Fourth Quarter and Full Year 2021 Results

INDIANAPOLIS, March 07, 2022 (GLOBE NEWSWIRE) — Infrastructure and Energy Alternatives, Inc. (NASDAQ: IEA) (“IEA” or the “Company”), a leading infrastructure company with renewable energy and specialty civil expertise, today announced results for the fourth quarter and full-year 2021. FOURTH QUARTER 2021 RESULTS(As compared to the Fourth Quarter 2020)Total Revenues of $544.1 million, +38.8% y/y Net Income of $31.7 million, versus a net loss of ($1.4) million Adjusted EBITDA of $46.2 million, +59.1% y/y Backlog of $2.9 billion increased 41% y/yFULL-YEAR 2021 RESULTS (As compared to the Full-Year 2020)Total Revenues of $2,078.4 million, +18.6% y/y Net Loss of $(83.7) million, versus Net Income of $0.7 millionNet Loss includes Loss on Extinguishment of Debt of $101.0 millionAdjusted EBITDA of $135.1 million, +5.6% y/yTotal...

Continue reading

LifeMD Reports Fourth Quarter and Full Year 2021 Results

FY2021 consolidated revenue of $92.9 million up 149% from the same year ago period; fourth quarter revenue of $27.4 million Fourth quarter Adjusted EPS of $(0.29), 19% sequential improvement versus the prior quarter Continued progress in reducing cash burn with a 21% sequential improvement in fourth quarter Operating Cash Flow versus prior quarter Record liquidity with over $41 million of cash as of year-end 2021 and no debt FY2022 revenue guidance of between $142 and $148 million; Company on track to achieve Adjusted EBITDA profitability by fourth quarter 2022NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) — LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the fourth quarter and year ended December 31, 2021. All figure comparisons are to the same year-ago quarter unless otherwise noted....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.